Menu

COVID-19 VA Grand Rounds Enduring Activity: Navigating Through This Health Crisis

When:
July 12, 2021 @ 7:00 am – July 12, 2022 @ 8:00 am
2021-07-12T07:00:00+00:00
2022-07-12T08:00:00+00:00

COVID-19 Frontline Therapies: Navigating Through This Health Crisis
and Optimizing Patient Care

 

View Activity

 

PROGRAM CHAIR

Shyam Kottilil, MD, PhD (PROGRAM CHAIR)
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

FACULTY PRESENTERS

Rohit Talwani, MD
Associate Professor
University of Maryland School of Medicine
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE VA Grand Rounds online activity provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. The online session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic, and will focus on optimizing outcomes for hospitalized and non-hospitalized patients with COVID-19 through the use of novel agents authorized for emergency use.

 

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veterans Affairs.

 

LEARNING OBJECTIVES

Upon the completion of this online program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care and update referral procedures as necessary
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating people with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with COVID-19.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Shyam Kottilil, MD, Ph.D. Discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals.    He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.
Rohit Talwani, MD Has nothing to disclose

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Cindy Lampner, MSLIS, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

 

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill